tradingkey.logo
tradingkey.logo
検索

AxoGen Inc

AXGN
ウォッチリストに追加
44.020USD
-2.170-4.70%
終値 07/01, 16:00ET15分遅れの株価
2.34B時価総額
損失額直近12ヶ月PER

詳細情報 AxoGen Inc 企業名

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

AxoGen Incの企業情報

企業コードAXGN
会社名AxoGen Inc
上場日Dec 17, 1986
最高経営責任者「CEO」Dale (Michael Donald)
従業員数451
証券種類Ordinary Share
決算期末Dec 17
本社所在地13631 Progress Blvd.
都市ALACHUA
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号32615
電話番号13864626817
ウェブサイトhttps://www.axogeninc.com/
企業コードAXGN
上場日Dec 17, 1986
最高経営責任者「CEO」Dale (Michael Donald)

AxoGen Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--

よくある質問

AxoGen Incの上位5名の株主は誰ですか?

AxoGen Incの上位5名の株主は以下のとおりです。Ms. Lindsey Hartley

AxoGen Inc(AXGN)の株式を保有している機関の数はいくつですか?

2026Q1時点で、AxoGen Incの株式を保有している機関は399社あり、保有株式の総市場価値は約48.71Mで、全体の91.60%を占めています。2025Q4と比較して、機関の持ち株は3148593.00増加しています。